Mouse MAb to KSHV/HHV-8 ORF59
Catalog #: 13-211-100
Size: 100 µg
In Stock
Mouse monoclonal antibody to lytic cycle-associated early protein (50 kDa), encoded by ORF 59 of Kaposi’s Sarcoma-Associated Herpesvirus/Human Herpesvirus 8. It is identified as DNA polymerase processivity factor (nuclear PF-8 protein), which is expressed in PEL cell lines (BCBL-1, BCP-1, BC-3, KS-1) 6-48 hours post-TPA induction. This antibody originates from ascites fluid and is purified by protein G chromatography.
For research use only.
APPLICATION FOR USE
- ELISA
- Western blot
- Dot blot
- IFA
- Other Protein-Based Assays
- IHC/ICC
- Flow Cytometry
- Antigen Detection
QUALITY CONTROL TESTING INCLUDES
- Sterility
- IFA
- Western blot
- SDS-PAGE
- Protein Concentration
SHIPPING AND STORAGE:
This product is shipped frozen on dry ice. Store at -20°C upon receipt. Avoid multiple freeze-thaw cycles as product degradation may result.
RECOMMENDATIONS:
Upon thawing, centrifuge the vial for a few seconds to remove residual droplets from the lid.
SAFE HANDLING RECOMMENDATIONS:
This biological preparation should be handled in accordance with biosafety guidelines defined in the BMBL, NIH-CDC HHS Publication No. (CDC) 21-1112.
How are Advanced Biotechnologies' Antibodies supplied? All antibodies are supplied frozen.
How should I store Advanced Biotechnologies' Antibodies? We recommend that all antibodies be aliquoted into single-use size portions and stored frozen at -20° C or below. Avoid multiple freeze-thaw cycles as this will affect antibody activity. Do not dilute and freeze – make final dilution just prior to use. When single-use aligquot volume is too small, glycerol can be added instead to make final 50% glycerol for long-term storage.
Will Advanced Biotechnologies' Antibodies work in Western blot? Not all antibodies work in Western blot. Please see the Certificate of Analysis to determine its suitability for Western blot use.
REFERENCE ARTICLES
Hartenian, E., Gilbertson, S., Federspiel, J., Cristea, I., and Glaunsinger, B. (2020). RNA decay during gammaherpesvirus infection reduces RNA polymerase II occupancy of host promoters but spares viral promoters. PLOS Pathogens 16, e1008269. https://doi.org/10.1371/journal.ppat.1008269
Park, M., Cho, H., Roh, S., Kim, S., and Myoung, J. (2019). Cell Type-Specific Interferon-γ-mediated Antagonism of KSHV Lytic Replication. Scientific Reports 9, 2372. https://doi.org/10.1038/s41598-019-38870-7
Garrigues, H., Howard, K., Barcy, S., Ikoma, M., Moses, A., Deutsch, G., Wu, D., Ueda, K., and Rose, T. (2017). Full-Length Isoforms of Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Accumulate in the Cytoplasm of Cells Undergoing the Lytic Cycle of Replication. Journal Of Virology 91, e01532-17. https://doi.org/10.1128/jvi.01532-17
Gramolelli, S., Weidner-Glunde, M., Abere, B., Viejo-Borbolla, A., Bala, K., Rückert, J., Kremmer, E., and Schulz, T. (2015). Inhibiting the Recruitment of PLCγ1 to Kaposi’s Sarcoma Herpesvirus K15 Protein Reduces the Invasiveness and Angiogenesis of Infected Endothelial Cells. PLOS Pathogens 11, e1005105. https://doi.org/10.1371/journal.ppat.1005105
Gotoh, K., Kariya, R., Alam, M., Matsuda, K., Hattori, S., Maeda, Y., Motoyama, K., Kojima, A., Arima, H., and Okada, S. (2014). The antitumor effects of methyl-β-cyclodextrin against primary effusion lymphoma via the depletion of cholesterol from lipid rafts. Biochemical And Biophysical Research Communications 455, 285-289. https://doi.org/10.1016/j.bbrc.2014.11.006
Rappocciolo, G., Hensler, H., Jais, M., Reinhart, T., Pegu, A., Jenkins, F., and Rinaldo, C. (2008). Human Herpesvirus 8 Infects and Replicates in Primary Cultures of Activated B Lymphocytes through DC-SIGN. Journal Of Virology 82, 4793-4806. https://doi.org/10.1128/jvi.01587-07
- New Product
- Available as Custom Product-Discontinued
- Limited Quantities Remaining-Discontinued
- Call For Availability
- Biohazard Category A
- Biohazard Category B
